Cyclooxygenase-2 inhibitors decrease interleukin-1β-stimulated prostaglandin E2 and Il-6 production by human gingival fibroblasts

Journal of Periodontology

Volumn 74, Issue 12, 2003, Pages 1754-1763

  Tipton, David A ^a   Flynn, Jon C ^a   Stein, Sidney H ^a   Dabbous, Mustafa Kh ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Aggressive; Bone resorption; COX 2 inhibitors; Fibroblasts; Interleukin 6; Periodontal; Periodontitis; Prostaglandin E2

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; INDOMETACIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; ROFECOXIB;

ADOLESCENT; ARTICLE; CASE REPORT; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; GINGIVA; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; MALE; NEUTROPENIA; PERIODONTITIS; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN SYNTHESIS INHIBITION; SCHOOL CHILD; SUPERNATANT;

ADOLESCENT; ANALYSIS OF VARIANCE; CELL LINE; CHILD; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DIMETHYL SULFOXIDE; DINOPROSTONE; FEMALE; FIBROBLASTS; GINGIVA; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; ISOENZYMES; MALE; MEMBRANE PROTEINS; PERIODONTITIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0842280605     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2003.74.12.1754     Document Type: Article

References (77)

1. Birkedal-Hansen H. Role of matrix metalloproteinases in human periodontal disease. J Periodontol 1993;64: 474-484.
2. Page RC. The role of inflammatory mediators in the pathogenesis of periodontal disease. J Periodont Res 1999;26: 230-242.
3. Page RC, Kjeldsen M, Holmstrup M, Bendtzen K. Marginal periodontitis and cytokines: A review of literature. J Periodontol 1993;64:1013-1022.
4. Birkedal-Hansen H. Role of cytokines and inflammatory mediators in tissue destruction. J Periodont Res 1993; 28:500-510.
5. Irwin CR, Myrillas TT. The role of IL-6 in the pathogenesis of periodontal disease. Oral Dis 1998;4:43-47.
6. Ishimi Y, Miyaura C, Jin CH, et al. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 1990;145:3297-3303.
7. Geivelis M, Tuner DW, Pederson ED, Lamberts BL. Measurements of interleukin-6 in gingival crevicular fluid from adults with destructive periodontal disease. J Periodontol 1993;63:980-983.
8. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 1. Proc Natl Acad Sci (USA) 1993;90:11924-11928.
9. Guillot JL, Pollock SM, Johnson RB. Gingival interleukin-6 concentration following phase I therapy. J Periodontol 1995;66:667-672.
10. Kent LW, Rahemtulla F, Michalek SM. Interleukin (IL)-1 and Porphyromonas gingivalis lipopolysaccharide stimulation of IL-6 production by fibroblasts derived from healthy or periodontally diseased human gingival tissue. J Periodontol 1999;70:274-282.
11. Takahashi K, Takashiba S, Nagai A, et al. Assessment of interleukin-6 in the pathogenesis of periodontal disease. J Periodontol 1994;65:147-153.
12. Dongari-Bagtzoglou AI, Ebersole JL. Increased presence of interleukin-6 (IL-6) and IL-8 secreting subpopulations in adult periodontitis. J Periodontol 1998;69: 899-910.
13. Agarwal S, Baran C, Piesco NP, et al. Synthesis of proinflammatory cytokines by human gingival fibroblasts in response to lipopolysaccharides and interleukin-1 beta. J Periodontal Res 1995;30:382-389.
14. 2 secretion as a determinant of periodontal disease statement. J Periodontol 1993;64:432-444.
15. Offenbacher S. Periodontal diseases: Pathogenesis. Ann Periodontol 1996;1:821-878.
16. Offenbacher S, Odle BM, Gray RC, Van Dyke TE. Crevicular fluid prostaglandin E levels as a measure of the periodontal disease status of adult and juvenile periodontitis patients. J Periodontal Res 1984;19:1-13.
17. Offenbacher S, Collins JG, Yalda B, Haradon G. Role of prostaglandins in high-risk periodontitis patients. In: Genco RJ, Hamada S, Lehner T, Mergenhagen S, eds. Molecular Pathogenesis of Periodontal Disease. Washington DC: ASM Press; 1994:203-214.
18. Agro A, Langdon C, Smith F, Richards CD. Prostaglandin E2 enhances interleukin 8 (IL-8) and IL-6 but inhibits GMCSF production by IL-1 stimulated human gingival fibroblasts. J Rheumatol 1996;23:862-868.
19. 2 potentiates interleukin-1β induced interleukin-6 production by human gingival fibroblasts. J Clin Periodontol 1996;23:635-640.
20. Waite IM, Saxon CA, Young A, Wagg BJ, Corbett M. The periodontal status of subjects receiving non-steroidal anti-inflammatory drugs. J Periodontal Res 1981;16:100-108.
21. Williams RC, Jeffcoat MK, Howell TH, et al. Altering the progression of human alveolar bone loss with the non-steroidal anti-inflammatory drug flurbiprofen. J Periodontol 1989;60:485-490.
22. Vane JR. Towards a better aspirin. Nature (London) 1984;367:215-216.
23. Eberhart CE, Dubois RN. Eicosanoids and the gastrointestinal tract. Gastroenterol 1995;109:285-301.
24. Smith WL. Prostanoid biosynthesis and mechanism of action. Am J Physiol 1992;263:F181-F191.
25. Wang S, Sun C, Gillanders. Genome scan for susceptibility to the complex disorder early onset periodontitis. Am J Hum Genet 1996;59(Suppl.):A240(Abstr. 1386).
26. Smith WL, DeWitt DL. Prostaglandin endoperoxide H synthase-1 and -2. Adv Immunol 1996;62:167-215.
27. Griswold DE, Adam JE. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): Rationale for selective inhibition and progress to date. Med Res Rev 1996;16:181-206.
28. Kreamer SA, Meada EA, DeWitt DL. Prostaglandin endoperoxide synthase gene structure: Identification of the transcriptional start site and the 5′-flanking regulatory sequences. Arch Biochem Biophys 1992;293:391-400.
29. Kujubu DA, Hershman HR. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 1992;267:7991-7994.
30. O'Neill GP, Ford-Hutchison AW. Statement of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993;330:156-160.
31. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci (USA) 1992;89:7384-7388.
32. Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of statement in response to cytokines. J Biol Chem 1993;268: 9049-9054.
33. Lee SH, Soyoola E, Chanmugam P, et al. Selective statement of mitogen-inducible cyclooxygenase in macrophage stimulated with lipopolysaccharide. J Biol Chem 1992;267: 25934-25938.
34. Morton RS, Dongari-Bagtzoglou AI. Regulation of gingival fibroblast interleukin-6 secretion by cyclosporine A. J Periodontol 1999;70:1464-1471.
35. 2 receptors in IL-1beta-stimulated human gingival fibroblasts. J Periodontal Res 2002;37:29-36.
36. Kornman KS, Crane A, Wang HY, et al. The interleukin-1 genotype as a severity factor in adult periodontal disease. J Clin Periodontol 1997;24:72-77.
37. Hempel SL, Martha H, Monick M, Hunninghake GW. Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest 1994;93:391-396.
38. Yucel-Lindberg T, Ahola H, Nilsson S, Carlstedt-Duke J, Modeer T. Interleukin-1β induces statement of cyclooxygenase-2 mRNA in human gingival fibroblasts. Inflammation 1995;19:49-56.
39. Noguchi K, Shitashige M, Yanai M, et al. Prostaglandin production via induction of cyclooxygenase-2 by human gingival fibroblasts stimulated with lipopolysaccharide. Inflammation 1996;20:555-568.
40. Mitchell JA, Akaraseereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs such as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci (USA) 1994;90:11693-11697.
41. Jouzeau J-Y, Terlain B, Abid A, Nedelec E, Netter P. Cyclooxygenase isoenzymes; how recent findings affect thinking about non steroidal anti-inflammatory drugs. Drugs 1997;53:563-582.
42. Tipton DA, Pabst MJ, Dabbous MKh. Interleukin-1β- and tumor necrosis factor α-independent monocyte stimulation of fibroblast collagenase activity. J Cell Biochem 1990;44:253-264.
43. Lowry O, Rosebrough N, Farr A, Randall R. Protein measurement with the folin-phenol reagent. J Biol Chem 1951;193:265-275.
44. Iniguez MA, Punzon C, Fresno M. Induction of cyclooxygenase-2 on activated T lymphocytes: Regulation of T cell activation by cyclogenase-2 inhibitors. J Immunol 1999; 163:111-119.
45. Noguchi K, Shitashige M, Ishikawa I. Involvement of cyclooxygenase-2 in interleukin-1α-induced prostaglandin production by human gingival periodontal ligament cells. J Periodontol 1999;70:902-908.
46. Dongari-Bagtzoglou AI, Ebersole JL. Production of inflammatory mediators and cytokines by human gingival fibroblasts following bacterial challenge. J Periodontal Res 1996;31:90-98.
47. Myrillas TT, Linden GJ, Marley JJ, Irwin CR. Cyclosporin A regulates interleukin-1beta and interleukin-6 expression in gingiva: Implications for gingival overgrowth. J Periodontol 1999;70:294-300.
48. 2 inhibits interleukin-6 release but not its transcription in human gingival fibroblasts stimulated with interleukin-1 beta or tumor necrosis factor-alpha. J Periodontol 1994;65:1122-1127.
49. Kent LW, Rahemtulla F, Hockett RD, Gilleland RC, Michalek SM. Effect of lipopolysaccharide and inflammatory cytokines on interleukin-6 production by healthy human gingival fibroblasts. Inf Immun 1998;66:608-614.
50. Yucel-Lindberg T, Nilsson S, Modeer T. Signal transduction pathways involved in the synergistic stimulation of prostaglandin production by interleukin-1beta and tumor necrosis factor alpha in human gingival fibroblasts. J Dent Res 1999;78:61-68.
51. Fosslien E. Biochemistry of cyclooxygenase (COX-2)-2 inhibitors and molecular physiology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000;37:431-502.
52. Noguchi K, Iwasaki K, Shitashige M, Endo H, Kondo H, Ishikawa I. Cyclooxygenase-2-dependent prostaglandin E2 down-regulates intercellular adhesion molecule-1 expression via EP2/EP4 receptors in interleukin-1beta-stimulated human gingival fibroblasts. J Dent Res 2000; 79:1955-1961.
53. Takigawa M, Takashiba S, Myokai F, et al. Cytokine-dependent synergistic regulation of interleukin-8 production from human gingival fibroblasts. J Periodontol 1994; 65:1002-1007.
54. Narayanan A, Voss T, Page R. Transcriptional regulation of fibroblast collagen synthesis by activated mononuclear cell supernatants. Biochem Biophys Res Commun 1985;131;1028-1032.
55. Postlethwaite A, Smith G, Mainardi C, Seyer J, Kang A. Lymphocyte modulation of fibroblast function in vitro: Stimulation and inhibition of collagen production by different effector molecules. J Immunol 1984;132:2470-2477.
56. Cullinan MP, Westerman B, Hamlet SM, et al. A longitudinal study of interleukin-1 gene polymorphisms and periodontal disease in a general adult population. J Clin Periodontol 2001;28:1137-1144.
57. Thomson WM, Edwards SJ, Dobson-Le DP, et al. IL-1 genotype and adult periodontitis among young New Zealanders. J Dent Res 2001;80:1700-1703.
58. Modeer T, Yucel-Lindberg T, Iinuma M, Lerner UH, Andersson G. Epidermal growth factor potentiates interleukin 1 and tumor necrosis factor-induced prostaglandin biosynthesis in human gingival fibroblasts. Cytokine 1993;5:198-204.
59. Manhart SS, Reinhardt RA, Payne JB, et al. Gingival cell IL-2 and IL-4 in early-onset periodontitis. J Periodontol 1994;65:807-813.
60. Dongari-Bagtzoglou AI, Ebersole JL. Gingival fibroblast cytokine profiles in Actinobacillus actinomycetemcomitans-associated periodontitis. J Periodontol 1996;67:871-878.
61. Blom MA, van Twillert MG, de Vries SC, et al. NSAIDS inhibit the IL-1 beta-induced IL-6 release from human post-mortem astrocytes: The involvement of prostaglandin E2. Brain Res 1997;777:210-218.
62. Tsuboi I, Tanaka H, Nakao M, Shichijo S, Itoh K. Non-steroidal anti-inflammatory drugs differentially regulate cytokine production in human lymphocytes and upregulation of TNFα, INFγ and IL-2 in contrast to downregulation of IL-6 production. Cytokine 1995;7:372-379.
63. 2 and production of interleukin 1, 6, and 8, in human and porcine explants in organ culture. J Pharm Pharmacol 1997;49:991-998.
64. Sirota L, Punsky I, Bessler H. Effect of indomethacin on IL-1beta, IL-6 and TNF alpha production by mononuclear cells of preterm newborns and adults. Acta Paediatr 2000;89:331-335.
65. Clausen PA, Flechtenmacher J, Haeuselmann HJ, Kuettner KE, Aydelotte MB, Iyer AP. Evidence of an eicosanoid contribution to IL-1 induction of IL-6 in human articular chondrocytes. Am J Ther 1996;3:101-108.
66. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853-6866.
67. Baeuerle PA, Baltimore D. NFκβ: Ten years after. Cell 1996;87:13-20.
68. Matasic R, Dietz AB, Vuk-Pavlovic S. Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. Immunology 2000;101:53-60.
69. Cianferoni A, Schroeder JT, Kim J et al. Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood 2001;97:1742-1749.
70. Lo CJ, Cryer HG, Fu M, Lo F. Regulation of macrophage eicosanoid generation is dependent on nuclear factor κβ. J Trauma Inj Inf Crit Care 1998;45:19-23.
71. Nakao S, Ogata Y, Shimizu-Sasaki E, Yamazaki M, Furuyama S, Sugiya H. Activation of NK-κβ is also necessary for IL-1β-induced COX-2 expression in human gingival fibroblasts (healthy). Mol Cell Biochem 2000;209: 113-121.
72. Morton RS, Dongari-Bagtzoglou AI. Cyclooxygenase-2 is upregulated in inflamed gingival tissues. J Periodontol 2001;72:461-469.
73. Eisengart CA, Mestre JR, Naama HA, et al. Prostaglandins regulate melanoma-induced cytokine production in macrophages. Cell Immunol 2000;204:143-149.
74. 2 in human lung fibroblast interleukin-11 production. Respir Med 1999;93:637-642.
75. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA. Systemic bioysynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci (USA) 1999;96:272-277.
76. Depré M, Ehrich E, Van Hecken A, et al. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000;56:167-174.
77. Bruguerolle B, Barbeau G, Belanger PM, Labrecque G. Pharmacokinetics of a sustained-release product of indomethacin in the elderly. Gerontology 1986;32:277-285.